Determination of bevantolol enantiomers in human plasma by coupled achiral-chiral high performance-liquid chromatography

Chirality

Volumn 19, Issue 7, 2007, Pages 528-535

  Joung, Weon Oh ^a   Tran, Quoc Trung ^a   Kwan, Seog Sin ^a   Jong, Seong Kang ^b   Kyeong, Ho Kim ^a  

^a Kangwon National University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Bevantolol; Enantiomer separation; HPLC; Propranolol; Solid phase extraction

Indexed keywords

BEVANTOLOL; PROPRANOLOL; SILICON DIOXIDE;

ARTICLE; CHIRALITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; PROPANOLAMINES; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM;

EID: 34250865568     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20410     Document Type: Article

References (20)

1. Drayer DE. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther 1986;2:125-133.
2. Drayer DE. Problems in therapeutic drug monitoring: the dilemma of enantiomeric drugs in man. Ther Drug Monit 1988;1:1-7.
3. Yamamoto M, Takayanagi Y, Nihashi S, Nomura Y, Nohira H. Bevantolol hydrochloride (nc-1400): absolute configuration and direct separation of the enantiomers. Chirality 1995;7:572-574.
4. Barrett AM, Cullum VA. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol 1968;1:43-55.
5. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizer. Clin Pharmacol Ther 1983;34:732-737.
6. Hsyu PH, Giacomini KM. Stereoselective renal clearance of pindolol in humans. J Clin Invest 1985;76:1720-1726.
7. 1-acid glycoprotein, and albumin. Clin Pharmacol Ther 1983;34:718-723.
8. Wainer IW. Drug Stereochemistry: analytical methods and pharmacology. New York: Marcel Dekker; 1993.
9. Randinitis EJ, Nelson C, Kinkel AW. Gas chromatographic determination of bevantolol in plasma. J Chromatogr 1984;308:345-349.
10. Nation RL, Peng GW, Chiou WL. High pressure liquid chromatographic method for simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma. J Chromatogr 1978;145:429-436.
11. Vermeij P, Brummelen PV. Pharmacokinetic parameters of bevantolol in volunteers. Eur J Clin Pharmacol 1986;30:375-377.
12. Selen A, Kinkel AW, Darke C, Greene DS, Welling PG. Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects. Eu J Clin Pharmacol 1986;30:699-704.
13. Hassan Y, Aboul-Enein , Vince S. Direct enantioselective separation of bevantolol by high performance liquid chromatography on normal and reverse cellulose chiral stationary phases. Biomed Chromatogr 1994;8:22-25.
14. Rose SE, Randinitis EJ. A high-performance liquid chromatographic assay for the enantiomers for bevantolol in human plasma. Pharm Res 1991;8:758-762.
15. Tan SC, Jackson SHD, Swift CG, Hutt AJ. Stereo specific analysis of the major metabolites of ibuprofen in urine by sequential achiral-chiral high performance liquid chromatography. J Chromatogr B 1997;701:53-63.
16. Mangani F, Luck G, Fraudeu C, Swift GG, Hutt AJ. On-line column-switching high performance liquid chromatography analysis of cardiovascular drugs in serum with automated sample clean-up and zone cutting technique to perform chiral separation. J Chromatogr B 1997;701:53-63.
17. Kim KH, Kim HJ, Kang JS, Mar W. Determination of metoprolol enantiomers in human urine by coupled achiral-chiral chromatography. J Pharm Biomed Anal 2000;22:377-384.
18. Kim KH, Heo SY, Hong SP, Lee BC. Enantiomeric purity test of Bevantolol by reversed phase high performance liquid chromatography after derivatization with 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl Isothiocyanate. Arch Pharm Res 2000;23:568-573.
19. FDA Guidance for industry. Bioanalytical method validation; May 2001. Available at http://www.fda.gov/cder/guidance/index.htm.
20. FDA Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: General considerations; March 2003. Available at http://www.fda.gov/cder/guidance/index.htm.